[1]张 萍a,王红义b,杨迎桂a,等.血清CEA,ProGRP,NSE和CYFRA21-1联合检测在肺癌诊断中的应用研究[J].现代检验医学杂志,2016,31(02):56-59.[doi:10.3969/j.issn.1671-7414.2016.02.017]
　ZHANG Pinga,WANG Hong-yib,YANG Ying-guia,et al.Clinical Application of Combined Detection of CEA,ProGRP,NSE and CYFRA21-1 in Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):56-59.[doi:10.3969/j.issn.1671-7414.2016.02.017]
点击复制

血清CEA,ProGRP,NSE和CYFRA21-1联合检测在肺癌诊断中的应用研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年02期
页码:
56-59
栏目:
论著
出版日期:
2016-06-01

文章信息/Info

Title:
Clinical Application of Combined Detection of CEA,ProGRP,NSE and CYFRA21-1 in Diagnosis of Lung Cancer
作者:
张 萍a; 王红义b; 杨迎桂a; 赵 晋a; 彭俊华a
兰州军区兰州总医院a.检验科; b.动物实验科,兰州 730050
Author(s):
ZHANG Pinga; WANG Hong-yib; YANG Ying-guia; ZHAO Jina; PENG Jun-huaa
Department of Clinical Laboratory, Lanzhou General Hospital of Lanzhou Command,PLA,Lanzhou 730050,China
关键词:
神经元特异性烯醇化酶;  细胞角蛋白片段19;  胃泌素释放前体;  肺癌;  诊断
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2016.02.017
文献标志码:
A
摘要:
目的 研究血清癌胚抗原(CEA)、胃泌素释放前体(ProGRP)、神经元特异性烯醇化酶(NSE)和细胞角蛋白19片段(CYFRA21-1)联合检测在肺癌诊断中的应用。方法 空腹取诊断明确的133例肺癌患者、67例肺部良性病变患者及同期66例体检健康者(对照组)的静脉血,用化学发光法检测血清CYFRA21-1,CEA,NSE和ProGRP水平,并计算敏感度、准确度和特异度。结果 CYFRA21-1,CEA,NSE和ProGR水平,肺癌患者血清分别为6.31±1.04 ng/ml,20.58±2.41 ng/ml,32.74±3.24 ng/ml和125.78±15.32 pg/ml,肺良性病变患者血清分别为1.93±0.52 ng/ml,2.93±0.82 ng/ml,10.49±1.93 ng/ml和48.32±6.72 pg/ml,对照组血清分别为1.56±0.45 ng/ml,2.67±0.74 ng/ml,8.34±1.2 ng/ml和35.78±4.2 pg/ml,肺癌患者血清CEA,ProGRP,NSE,CYFRA21-1水平均高于肺良性病变患者(t=1.48～2.78,P=0.13～0.25)和对照组(t=1.981～2.371,P=0.21～0.41),差异均有统计学意义(P<0.05)。CYFRA21-1,NSE,CEA和ProGRP单项检测肺癌的敏感度分别为61.65%,45.86%,52.63%和63.91%,准确度为72.36%,63.81%,67.34%和74.87%。联合两项、三项检测肺癌,敏感度为72%～89%,准确度为78.89%～89.44%。四项联合检测肺癌的敏感度(92.48%)、准确度(90.45%)最高。结论 血清标志物能较好地诊断肺癌,联合多种血清学指标检测可提高肺癌诊断的敏感度、准确度。
Abstract:
Objective To study the clinical application ofcombined detection of CEA,ProGRP,NSE and CYFRA21-1 in diagnosis of lung cancer.Methods Fasting venous blood samples were collected from 133 cases with lung cancer,67 cases with benign pulmonary disease and 66 healthy volunteers(control),the serum level of CEA,ProGRP,NSE and CYFRA21-1 were detected by chemilumine-scence method and the sensitivity rate,accuracy rate and specificity rate were calculate.Results The serumlevel of CYFRA21-1,CEA,NSE and ProGRP from lung cancer patients was 6.31±1.04 ng/ml,20.58±2.41 ng/ml 32.74±3.24 ng/ml and 125.78±15.32 pg/ml,respectively.The level of CYFRA21-1,CEA,NSE,and ProGRP from benign pulmonarydisease was 1.93±0.52 ng/ml,2.93±0.82 ng/ml,10.49±1.93 ng/ml and 48.32±6.72 pg/ml,respectively.The level of CYFRA21-1,CEA,ProGRP and NSE and from control was 2.67±0.74 ng/ml,35.78±4.2 pg/ml,8.34±1.2 ng/ml and1.56±0.45 ng/ml,respectively.The level of CEA,ProGRP,NSE and CYFRA21-1from lung cancer were higher than that from benign pulmonary disease(t=1.48～2.78,P=0.13～0.25)and that from control(t=1.981～2.371,P=0.21～0.41),respectively,all of them was a statistical significance(P<0.05).The sensitivity rate of only CEA,ProGRP,NSE and CYFRA21-1 detection in diagnosis of lung cancer was 61.65%,45.86%,52.63% and 63.91%,respectively.The accuracy rate of only CEA,ProGRP,NSE and CYFRA21-1 detection was 72.36%,63.81%,67.34% and 74.87%,respectively.Combining detection of two or threeserum tumor markers in diagnosis of lung cancer,the sensitivity rate was 72%～89%,the accuracy rate was 78.89%～89.44% and the sensitivity rate(92.48%)and accuracy rate(90.45%)of combined detection of four serum tumor markers wasthe highest.Conclusion Serum markers can better diagnosis of lung cancer,combined detection of serum tumor markers can increase the sensitivity rate and accuracy rate in diagnosis of lung cancer.

参考文献/References:

[1] Kadaria D,Archie DS,Sultanali I,et al.Dual time po-int positron emission tomography/computed tomography scan in evaluation of intrathoraciclesions in an area endemic for histoplasmosis and with high prevalence of sarcoidosis[J].Am J Med Sci,2013,346(5):358-362.
[2] Chen WQ,Zhang SW,Zou XN.Evaluation on the incidence,mortality and tendency of lung cancer in China[J].Thoracic Cancer,2010,1(1):35-40.
[3] 高 娜,王建清.血清学肿瘤标志物在肺癌诊断中的临床研究[J].延安大学学报(医学科学版),2014,12(4):21-24. Gao N,Wang JQ.The clinical research on the serum tumor markers indiagnosis of lung cancer[J].J Yanan Univ(Med Sci),2014,12(4):21-24.
[4] 张 艳,刘 晶,杨梦迪.非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义[J].临床药物治疗杂志,2014,12(5):35-39. Zhang Y,Liu J,Yang MD.Clinical significance of serum tumor markers in predicting outcomes of targeted therapy in advanced non-small cell Lung cancer[J].Clin Med J,2014,12(5):35-39.
[5] 金 欣,陈健魁,佟雅丽,等.血清ProGRP,NSE,CY-FRA21-1联合检测对肺癌诊断和治疗的临床意义[J].中国卫生检验杂志,2007,17(6):1008-1009,1022. Jin X,Chen JK,Tong YL,et al.Clinical significance of tumor marker ProGRP,NSE,CYFRA21-1 in lung cancer[J].Chin J Health Lab Techno,2007,17(6):1008-1009,1022.
[6] Yu D,Du K,Liu T,et al.Prognostic value of tumor markers,NSE,CA125 and SCC in operable NSCLC patients[J].Int J Mol Sci,2013,14(6):11145-11156.
[7] 黄 芳,耿 燕,李婷婷,等.血清CEA,CA125,NS-E,CY FRA21-1联合检测对肺癌的诊断价值[J].现代检验医学杂志,2008,23(6):97-99. Wang F,Gen Y,Li TT,et al.Diagnostic value of co-mbined determinations of serum tumor markers(CEA,CA125,NSE and CYFRA21-1)levels in patientswith lung cancer[J].J Mod Lab Med,2008,23(6):97-99.
[8] Lin XF,Wang XD,Sun DQ,et al.High serum CEA and CYFRA21-1 levels after a two-cycle adjuvant chemotherapy for NSCLC:possible poor prognostic factors [J].Cancer Biol Med,2012,9(4):270-273.
[9] Cedres S,Nunez I,Longo M,et al.Serum tumor ma-rkers CEA,CYFRA21-1,and CA-125 are associated with worse prognosis in advanced non-small-cell Lung Cancer(NSCLC)[J].Clinical Lung Cancer,2011,12(3):172-179.
[10] 万程彬.研究血清多种肿瘤标志物联合检测在肺癌诊断中的价值[J].中国医学创新,2014,11(36):60-62. Wan CB.Study of serum tumor markers in diagnosis of lung cancer[J].MedInnova Chin,2014,11(36):60-62.

相似文献/References:

[1]卢美红,鞠少卿,丛 辉,等.南通地区健康人群血清NSE电化学发光法检测参考区间的调查[J].现代检验医学杂志,2018,33(04):59.[doi:10.3969/j.issn.1671-7414.2018.04.015]
　LU Mei-hong,JU Shao-qing,CONG Hui,et al.Investigate of Serum NSE Reference Range of Healthy People in Nantong with Electrochemiluminescence[J].Journal of Modern Laboratory Medicine,2018,33(02):59.[doi:10.3969/j.issn.1671-7414.2018.04.015]
[2]彭　琦a,程少鹏b,陈辅萍a.非小细胞肺癌组织中NSE 的基因表达及与患者临床特征的相关性研究[J].现代检验医学杂志,2020,35(03):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
　PENG Qia,CHENG Shao-pengb,CHEN Fu-pinga.Correlation between NSE Gene Expression and Serum NSE Level in Tumor Tissues and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(02):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
[3]徐翠香,王建华,武　敏,等.胃癌患者血清CA724，NSE和 PGR水平联合检测对肿瘤临床病理分期及淋巴结转移的诊断价值[J].现代检验医学杂志,2021,36(01):6.[doi:10.3969/j.issn.1671-7414.2021.01.002]
　XU Cui-xiang,WANG Jian-hua,WU Min,et al.Diagnostic Value of Combined Detection of Serum CA724, NSE and PGR Levels in Patients with Gastric Cancer for Tumor Clinical Pathological Stage and Lymph Node Metastasis[J].Journal of Modern Laboratory Medicine,2021,36(02):6.[doi:10.3969/j.issn.1671-7414.2021.01.002]
[4]王妮娜,李晓花,陈敏丽,等.肺癌患者血清NSE，SCC，CA125及 CYFRA21-1水平检测在不同病理类型早期诊断和化疗疗效评价中的应用价值[J].现代检验医学杂志,2021,36(01):33.[doi:10.3969/j.issn.1671-7414.2021.01.009]
　WANG Ni-na,LI Xiao-hua,CHEN Min-li,et al.Application Value of Serum NSE, SCC, CA125 and CYFRA21-1 in Patients of Lung Cancer for Early Diagnosis and Evaluation of Chemotherapy Efficacy in Patients with Different Pathological Types[J].Journal of Modern Laboratory Medicine,2021,36(02):33.[doi:10.3969/j.issn.1671-7414.2021.01.009]
[5]朱　娇a,孙国才b,刘素荣a,等.食管癌患者血清神经元特异性烯醇化酶与长链非编码RNA ITGA9-AS1水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
　ZHU Jiaoa,SUN Guo-caib,LIU Su-ronga,et al.Experimental Diagnostic Value of Combined Detection of SerumNeuron-Specific Enolase and Long Non-Coding RNA ITGA9-AS1 inPatients with Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(02):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
[6]董旭才,李 斌,曹聪聪,等.临床实验室单标本气动传输系统改进对血清NSE 和Cyfra21-1 检测结果的影响及效果评价[J].现代检验医学杂志,2023,38(04):169.[doi:10.3969/j.issn.1671-7414.2023.04.031]
　DONG Xucai,LI Bin,CAO Congcong,et al.Effect and Evaluation of Single Specimen Pneumatic Transmission System Improvement on Serum NSE and Cyfra21-1 Detection in Clinical Laboratory[J].Journal of Modern Laboratory Medicine,2023,38(02):169.[doi:10.3969/j.issn.1671-7414.2023.04.031]

备注/Memo

备注/Memo:
作者简介:张 萍(1983-),女,本科,主管技师,主要从事肿瘤标志物检测与研究。 通讯作者:彭俊华,E-mail:junhua p@126.com。
更新日期/Last Update: 2016-02-20